• Je něco špatně v tomto záznamu ?

The effect of oral butyrate on colonic short-chain fatty acid transporters and receptors depends on microbial status

K. Vagnerová, T. Hudcovic, M. Vodička, P. Ergang, P. Klusoňová, P. Petr Hermanová, D. Šrůtková, J. Pácha

. 2024 ; 15 (-) : 1341333. [pub] 20240326

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013104

Butyrate, a metabolite produced by gut bacteria, has demonstrated beneficial effects in the colon and has been used to treat inflammatory bowel diseases. However, the mechanism by which butyrate operates remains incompletely understood. Given that oral butyrate can exert either a direct impact on the gut mucosa or an indirect influence through its interaction with the gut microbiome, this study aimed to investigate three key aspects: (1) whether oral intake of butyrate modulates the expression of genes encoding short-chain fatty acid (SCFA) transporters (Slc16a1, Slc16a3, Slc16a4, Slc5a8, Abcg2) and receptors (Hcar2, Ffar2, Ffar3, Olfr78, Olfr558) in the colon, (2) the potential involvement of gut microbiota in this modulation, and (3) the impact of oral butyrate on the expression of colonic SCFA transporters and receptors during colonic inflammation. Specific pathogen-free (SPF) and germ-free (GF) mice with or without DSS-induced inflammation were provided with either water or a 0.5% sodium butyrate solution. The findings revealed that butyrate decreased the expression of Slc16a1, Slc5a8, and Hcar2 in SPF but not in GF mice, while it increased the expression of Slc16a3 in GF and the efflux pump Abcg2 in both GF and SPF animals. Moreover, the presence of microbiota was associated with the upregulation of Hcar2, Ffar2, and Ffar3 expression and the downregulation of Slc16a3. Interestingly, the challenge with DSS did not alter the expression of SCFA transporters, regardless of the presence or absence of microbiota, and the effect of butyrate on the transporter expression in SPF mice remained unaffected by DSS. The expression of SCFA receptors was only partially affected by DSS. Our results indicate that (1) consuming a relatively low concentration of butyrate can influence the expression of colonic SCFA transporters and receptors, with their expression being modulated by the gut microbiota, (2) the effect of butyrate does not appear to result from direct substrate-induced regulation but rather reflects an indirect effect associated with the gut microbiome, and (3) acute colon inflammation does not lead to significant changes in the transcriptional regulation of most SCFA transporters and receptors, with the effect of butyrate in the inflamed colon remaining intact.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013104
003      
CZ-PrNML
005      
20240726151524.0
007      
ta
008      
240723e20240326sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2024.1341333 $2 doi
035    __
$a (PubMed)38595917
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vagnerová, Karla $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
245    14
$a The effect of oral butyrate on colonic short-chain fatty acid transporters and receptors depends on microbial status / $c K. Vagnerová, T. Hudcovic, M. Vodička, P. Ergang, P. Klusoňová, P. Petr Hermanová, D. Šrůtková, J. Pácha
520    9_
$a Butyrate, a metabolite produced by gut bacteria, has demonstrated beneficial effects in the colon and has been used to treat inflammatory bowel diseases. However, the mechanism by which butyrate operates remains incompletely understood. Given that oral butyrate can exert either a direct impact on the gut mucosa or an indirect influence through its interaction with the gut microbiome, this study aimed to investigate three key aspects: (1) whether oral intake of butyrate modulates the expression of genes encoding short-chain fatty acid (SCFA) transporters (Slc16a1, Slc16a3, Slc16a4, Slc5a8, Abcg2) and receptors (Hcar2, Ffar2, Ffar3, Olfr78, Olfr558) in the colon, (2) the potential involvement of gut microbiota in this modulation, and (3) the impact of oral butyrate on the expression of colonic SCFA transporters and receptors during colonic inflammation. Specific pathogen-free (SPF) and germ-free (GF) mice with or without DSS-induced inflammation were provided with either water or a 0.5% sodium butyrate solution. The findings revealed that butyrate decreased the expression of Slc16a1, Slc5a8, and Hcar2 in SPF but not in GF mice, while it increased the expression of Slc16a3 in GF and the efflux pump Abcg2 in both GF and SPF animals. Moreover, the presence of microbiota was associated with the upregulation of Hcar2, Ffar2, and Ffar3 expression and the downregulation of Slc16a3. Interestingly, the challenge with DSS did not alter the expression of SCFA transporters, regardless of the presence or absence of microbiota, and the effect of butyrate on the transporter expression in SPF mice remained unaffected by DSS. The expression of SCFA receptors was only partially affected by DSS. Our results indicate that (1) consuming a relatively low concentration of butyrate can influence the expression of colonic SCFA transporters and receptors, with their expression being modulated by the gut microbiota, (2) the effect of butyrate does not appear to result from direct substrate-induced regulation but rather reflects an indirect effect associated with the gut microbiome, and (3) acute colon inflammation does not lead to significant changes in the transcriptional regulation of most SCFA transporters and receptors, with the effect of butyrate in the inflamed colon remaining intact.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hudcovic, Tomáš $u Institute of Microbiology, Czech Academy of Sciences, Nový Hrádek, Czechia
700    1_
$a Vodička, Martin $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Ergang, Peter $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Klusoňová, Petra $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Petr Hermanová, Petra $u Institute of Microbiology, Czech Academy of Sciences, Nový Hrádek, Czechia
700    1_
$a Šrůtková, Dagmar $u Institute of Microbiology, Czech Academy of Sciences, Nový Hrádek, Czechia
700    1_
$a Pácha, Jiří $u Institute of Physiology, Czech Academy of Sciences, Prague, Czechia $u Department of Physiology, Faculty of Science, Charles University, Prague, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 15 (20240326), s. 1341333
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38595917 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151517 $b ABA008
999    __
$a ok $b bmc $g 2125603 $s 1224967
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1341333 $e 20240326 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...